Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 12:10:107-114.
doi: 10.2147/PGPM.S126305. eCollection 2017.

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome

Karin B Mirzaev  1 , Elena M Zelenskaya  2 , Olga L Barbarash  3 , Vladimir I Ganyukov  3 , Konstantin A Apartsin  4   5 , Natalya O Saraeva  4 , Konstantin Y Nikolaev  6   7 , Kristina A Ryzhikova  1 , Galina I Lifshits  2   5   7 , Dmitry A Sychev  1
Affiliations

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome

Karin B Mirzaev et al. Pharmgenomics Pers Med. .

Abstract

Purpose: The aim of this study is to investigate the frequency of CYP2C19*2, *3 allelic variants, associated with poor response to clopidogrel, and CYP2C19*17, associated with excessive response to clopidogrel, in patients with acute coronary syndrome (ACS) from Siberia and Moscow regions of Russia.

Patients and methods: The study included 512 ACS patients who were subsequently treated with coronary arterial stenting. The subjects assigned were from the cities of Central (Novosibirsk, Kemerovo), Eastern (Irkutsk), Northern (Surgut) Siberia regions and from Moscow region. The mean age of patients enrolled was 63.9±10.9 years. Among the assigned subjects, the proportion of men accounted for 80% and women 20%.

Results: According to the results obtained in the present study, from 16% up to 27.5% of patients in different regions of Russia have at least one CYP2C19 "poor metabolizer" (PM) allele variant affecting clopidogrel metabolism and, therefore, suppressing its antiplatelet activity. CYP2C19*17 allele variant was identified with the frequency of 15.4% up to 33.3%. The study revealed the presence of statistically significant differences in CYP2C19*3 allele frequency between the Russian ethnic group patients from Eastern and Central Siberia (p=0.001; odds ratio=1.05 [95% confidence interval 1.01-1.09]).

Conclusion: The study revealed statistically significant differences between the allele frequencies in Eastern and Central Siberia, which can probably be caused by a considerable number of Buryats inhabiting Eastern Siberia.

Keywords: P2Y12 receptor inhibitors; clopidogrel resistance; dual antiplatelet therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure Part of the research on the frequencies of CYP2C19*2, *3, and *17 gene polymorphisms observed in the patients of Moscow region has been supported by Russian Science Foundation – project 16–15-00227 “Fundamental research and exploratory research conducted in the top priority areas”. Part of the research on the frequencies of CYP2C19*2, *3, and *17 gene polymorphisms observed in the patients of Siberian region has been conducted under the government contract “Development of a portable system aimed at multiparameter control of human coagulation system functional properties”; agreement No 14.697.21.0066; project unique identifier is RFMEFI60714X0066. The authors report no other conflicts of interest in this work.

References

    1. Information bulletin WHO: Top 10 causes of death worldwide. [Accessed February 03, 2013]. Available from: http://www.who.int/mediacentre/factsheets/fs310/ru/. Updated January 2017.
    1. Mancia G, Fagard R, Narkiewicz K, et al. Рекомендации по лечению артериальной гипертонии ESH/ESC 2013 [Guidelines on hypertension treatment ESH/ESC 2013] Ros Kardiol Zhurnal [Russian J Cardiol] 2014;1:7–94. Russian.
    1. Knauer NY, Lifshits GI. Молекулярно-генетический подход к оптимизации современной антиагрегантной терапии [Molecular genetic approach to contemporary antiplatelet therapy optimization] Bull East-Siberian Sci Center SB RAMS. 2012;2–1(84):143–152. Russian.
    1. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(1):1821–1830. - PMC - PubMed
    1. Knauer NY, Lifshits GI, Voronina EN, et al. Информативность генетических маркеров для оптимизации персонализированной терапии клопидогрелом [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel] Kardiologiia. 2013;53(8):72–75. Russian. - PubMed

LinkOut - more resources